


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>			
			
Complete if Known			
Application Number		10/581,401	
Filing Date		June 1, 2006	
First Named Inventor		Jean-Christophe PAGES	
Art Unit		TBD 1633	
Examiner Name		TBD Marvich	
Attorney Docket Number		5058-108 US	
Sheet	1	of	1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴				
/M.M./		WO	98/13511 A1	04-02-1998	GOVERNMENT OF U.S.A.		
/M.M./		WO	03/072771 A2	09-04-2003	WAHLFORS et al.		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FEB 07 2008



Substitute for form 1449b

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

<i>Application Number</i>	10/581,401
<i>Filing Date</i>	June 1, 2006
<i>First Named Inventor</i>	Jean-Christophe PAGES
<i>Art Unit</i>	TBD
<i>Examiner Name</i>	TBD

Attorney Docket Number 5058-108 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/M.M./	1.	ROLLS, M.M. et al., "Novel Infectious Particles Generated by Expression of the Vesicular Stomatitis Virus Glycoprotein from a Self-Replicating RNA", Cell, November 4, 1994, pgs. 497-506, vol. 79, Cell Press	
	2.	ROLLS, M.M. et al., "Expression of Additional Genes in a Vector Derived from a Minimal RNA Virus", Virology, (1996), pgs. 406-411, no. 0211, Academic Press, Inc.	
	3.	LEBEDEVA, I. et al., "Infectious Particles Derived from Semliki Forest Virus Vectors Encoding Murine Leukemia Virus Envelopes", Journal of Virology, Sept. 1997, pgs. 7061-7067, vol. 71, no. 9, American Society for Microbiology	
	4.	RUSSELL, S.J. et al., "Modifying the Host Range Properties of Retroviral Vectors", The Journal of Gene Medicine, 1999, pgs. 300-311, vol. 1, John Wiley & Sons, Ltd. 1999	
	5.	SALONEN, A. et al., "Properly Folded Nonstructural Polyprotein Directs the Semliki Forest Virus Replication Complex to the Endosomal Compartment", Journal of Virology, February 2003, pgs. 1691-1702, vol. 77, no. 3, American Society for Microbiology	
	6.	NALDINI, L. et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", Science, April 12, 1996, pgs. 263-267, vol. 272	
	7.	LIU, M.L. et al., "Pseudotransduction of Hepatocytes by Using Concentrated Pseudotyped Vesicular Stomatitis Virus G Glycoprotein (VSV-G)-Moloney Murine Leukemia Virus-Derived Retrovirus Vectors: Comparison of VSV-G and Amphotropic Vectors for Hepatic Gene Transfer", Journal of Virology, April 1996, pgs. 2497-2505, vol. 70, no. 4, American Society for Microbiology	
	8.	LUNDSTROM, K. et al., "Novel Semliki Forest Virus Vectors with Reduced Cytotoxicity and Temperature Sensitivity for Long-Term Enhancement of Transgene Expression", Molecular Therapy, February 2003, pgs. 202-209, vol. 7, no. 2, The American Society of Gene Therapy	
↓	9.	MURIAUX, D. et al., "RNA is a Structural Element in Retrovirus Particles", Proc. Natl. Acad. Science, April 24, 2001, pgs. 5246-5251, vol. 98, no. 9	
/M.M./	10.	Li, K.J. et al., "Packaging of Intron-Containing Genes into Retrovirus Vectors by Alphavirus Vectors", Cell Biology, March 1998, pgs. 3650-3654, vol. 95, Proc. Natl. Acad. Science, USA	

Examiner Signature	/Maria Marvich/	Date Considered	04/05/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-A PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known	
Application Number	10/581,401
Filing Date	June 1, 2006
First Named Inventor	Jean-Christophe PAGES
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	5058-108 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/M.M./	11.	WAHLFORSS, J.J. et al., "Semliki Forest Virus-Mediated Production of Retroviral Vector RNA in Retroviral Packaging Cells", Human Gene Therapy, November 20, 1997, pgs. 2031-2041, vol. 8, Mary Ann Liebert, Inc.	
/M.M./	12.	LUNDSTROM, K., "Alphavirus Vectors as Tools in Cancer Gene Therapy", Technology in Cancer Research & Treatment, February 2002, pgs. 83-88, vol. 1, no. 1, Adenine Press	
/M.M./	13.	Dept. of Molecular Pharmacology, Standford University, Medical Center - Retroviral Systems Nolan Lab, website reference, http://www.standford.edu/group/nolan/retroviral_systems/retsys.html , pgs. 1-2 downloaded 12/17/07	

Examiner Signature

/Maria Marvich/

Date Considered

04/05/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.